5 Einträge gefunden

1. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

   1. Mai, Elias K
   2. Huhn, Stefanie
   3. Miah, Kaya
   4. Poos, Alexandra M
   5. Scheid, Christof
   6. Weisel, Katja C
   7. Bertsch, Uta

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

   1. Mai, Elias K
   2. Miah, Kaya
   3. Bertsch, Uta
   4. Dürig, Jan
   5. Scheid, Christof
   6. Weisel, Katja C
   7. Kunz, Christina

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

   1. Salwender, Hans
   2. Elmaagacli, Ahmet
   3. Merz, Maximilian
   4. Miah, Kaya
   5. Benner, Axel
   6. Haenel, Mathias
   7. Jehn, Christian

   2021 - Forschungsinformationssystem des UKE
4. Response-adapted lenalidomide maintenance in newly diagnosed myeloma:results from the phase III GMMG-MM5 trial

   1. Goldschmidt, Hartmut
   2. Mai, Elias K
   3. Dürig, Jan
   4. Scheid, Christof
   5. Weisel, Katja C
   6. Kunz, Christina
   7. Bertsch, Uta

   2020 - Forschungsinformationssystem des UKE
5. Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

   1. Weisel, Katja C
   2. Scheid, Christof
   3. Zago, Manola
   4. Besemer, Britta
   5. Mai, Elias K
   6. Haenel, Mathias
   7. Duerig, Jan

   2019 - Forschungsinformationssystem des UKE